Wouter Vervecken

USPTO Granted Patents = 18 (Patent Applications = 7)

CIPO Patents = 7 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 3.3

ph-index = 9

Forward Citations = 136(Granted Patents)

Location History:

Ghent-Ledeberg, BE (2009 - 2011)
Gent-Ledeberg, BE (2011 - 2013)
Landskouter-Oosterzele, BE (2021)
Landskouter, BE (2015 - 2022)

Company Filing History:

Research Corporation Technologies, Inc.

patents

5. 2 out of 185

Vrije Universiteit Brussel

patents

where one patent can have more than one assignee

Years Active: 2009-2022

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11225646 - Yeast strains producing mammalian-like complex n-glycans (2022-01-18),

2. 11040114 - Human alpha-N-acetylgalactosaminidase polypeptide (2021-06-22),

3. 10648044 - Methods and materials for treatment of Pompe's disease (2020-05-12),

4. 10392609 - Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose (2019-08-27),

5. 10344310 - De-mannosylation of phosphorylated N-glycans (2019-07-09),

6. 10287557 - Yeast strains producing mammalian-like complex N-glycans (2019-05-14),

7. 10023854 - Microorganisms genetically engineered to have modified N-glycosylation activity (2018-07-17),

8. 10011857 - Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins (2018-07-03),

9. 9689015 - De-mannosylation of phosphorylated N-glycans (2017-06-27),

10. 9598682 - Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose (2017-03-21),

11. 9347050 - Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins (2016-05-24),

12. 9249399 - Methods and materials for treatment of pompe's disease (2016-02-02),

13. 9222083 - Microorganisms genetically engineered to have modified N-glycosylation activity (2015-12-29),

14. 9206408 - Microorganisms genetically engineered to have modified N-glycosylation activity (2015-12-08),

15. 8597906 - Glycosylation of molecules (2013-12-03),

Title: Wouter Vervecken: Pioneering Innovations in Glycobiology

Introduction

Wouter Vervecken, an accomplished inventor based in Landskouter, Belgium, has made significant contributions to the field of glycobiology, with a remarkable portfolio of 18 patents. His innovative approaches and groundbreaking research have positioned him as a key figure in the development of new therapeutic methods and biotechnological applications.

Latest Patents

Among his latest patents, Vervecken has developed yeast strains that produce mammalian-like complex N-glycans. This invention outlines methods and genetically engineered fungal cells that facilitate the production of target molecules containing mammalian-like complex N-glycans or their intermediates, enhancing the understanding of mammalian glycosylation pathways. Another significant invention is centered around the human alpha-N-acetylgalactosaminidase polypeptide. This patent presents new forms of the polypeptide and its functionally active variants, along with nucleic acids encoding these forms. Notably, this invention holds potential for treating conditions such as Fabry disease, Schindler disease, and Kanzaki disease.

Career Highlights

Throughout his career, Wouter Vervecken has been associated with several companies that have shaped his research endeavors. Noteworthy among them are Oxyrane UK Limited and Vib Vzw, where he has contributed to pioneering biopharmaceutical developments.

Collaborations

Vervecken has collaborated with notable professionals in the field, including Kathleen Camilla Telesphore Alida Maria Piens and Nico Luc Marc Callewaert. These partnerships highlight his commitment to teamwork and the sharing of ideas, essential for driving innovation in research.

Conclusion

Wouter Vervecken's impressive array of patents and collaborations underscores his impact on the biotechnology landscape. His innovations in glycobiology not only advance scientific understanding but also pave the way for new therapeutic applications that can benefit countless individuals suffering from glycosylation-related diseases.

This text is generated by artificial intelligence and may not be accurate.